Cite
Yarchoan M, Cope L, Ruggieri AN, et al. Multicenter randomized phase II trial of atezolizumab with or without cobimetinib in biliary tract cancers. J Clin Invest. 2021;131(24)doi: 10.1172/JCI152670.
Yarchoan, M., Cope, L., Ruggieri, A. N., Anders, R. A., Noonan, A. M., Goff, L. W., Goyal, L., Lacy, J., Li, D., Patel, A. K., He, A. R., Abou-Alfa, G. K., Spencer, K., Kim, E. J., Davis, S. L., McRee, A. J., Kunk, P. R., Goyal, S., Liu, Y., Dennison, L., Xavier, S., Mohan, A. A., Zhu, Q., Wang-Gillam, A., Poklepovic, A., Chen, H. X., Sharon, E., Lesinski, G. B., & Azad, N. S. (2021). Multicenter randomized phase II trial of atezolizumab with or without cobimetinib in biliary tract cancers. The Journal of clinical investigation, 131(24), . https://doi.org/10.1172/JCI152670
Yarchoan, Mark, et al. "Multicenter randomized phase II trial of atezolizumab with or without cobimetinib in biliary tract cancers." The Journal of clinical investigation vol. 131,24 (2021). doi: https://doi.org/10.1172/JCI152670
Yarchoan M, Cope L, Ruggieri AN, Anders RA, Noonan AM, Goff LW, Goyal L, Lacy J, Li D, Patel AK, He AR, Abou-Alfa GK, Spencer K, Kim EJ, Davis SL, McRee AJ, Kunk PR, Goyal S, Liu Y, Dennison L, Xavier S, Mohan AA, Zhu Q, Wang-Gillam A, Poklepovic A, Chen HX, Sharon E, Lesinski GB, Azad NS. Multicenter randomized phase II trial of atezolizumab with or without cobimetinib in biliary tract cancers. J Clin Invest. 2021 Dec 15;131(24). doi: 10.1172/JCI152670. PMID: 34907910; PMCID: PMC8670844.
Copy
Download .nbib